Lord Freyberg – 2016 Parliamentary Question to the Department of Health
The below Parliamentary question was asked by Lord Freyberg on 2016-09-05.
To ask Her Majesty’s Government what measures they intend to put in place to ensure that patients with radioiodine refractory differentiated thyroid cancer can receive all effective clinical treatments currently available through EU authorisation.
Lord Prior of Brampton
Changes to the process for evaluating cancer drugs were introduced at the end of July 2016 as part of the new arrangements for the Cancer Drugs Fund (CDF). Under the new arrangements, all new cancer drugs are expected to be referred to the National Institute for Health and Care Excellence (NICE) for evaluation through its technology appraisal programme. In some cases, NICE will recommend that the cancer drug is funded through the CDF, which enables further evaluation of its place in therapy. Drugs that have a European Union (EU) or United Kingdom marketing authorisation for radioiodine refractory differentiated thyroid cancer will therefore be reviewed under this process and if found to be clinically and cost effective will become established treatment within the National Health Service.
The UK remains a member of the EU until Article 50 negotiations have concluded. EU law continues to apply and ongoing compliance with EU law is considered important in facilitating orderly transition, for negotiating purposes, and to offer certainty in the meantime. As long as the UK is subject to EU law, the present arrangements remain in place.
